Study design and rationale for a randomised, placebo-controlled, double-blind study to assess the efficacy of selumetinib (AZD6244; ARRY-142886) in combination with dacarbazine in patients with metastatic uveal melanoma (SUMIT)

BACKGROUND: Uveal melanoma is characterised by mutations in GNAQ and GNA11, resulting in Ras/Raf/MEK/ERK pathway activation. Treatment with selumetinib (AZD6244, ARRY-142886), a MEK1/2 inhibitor, results in antitumour effects in uveal melanoma pre-clinical models. A randomised phase II trial demonst...

Descripción completa

Detalles Bibliográficos
Autores principales: Carvajal, Richard D., Schwartz, Gary K., Mann, Helen, Smith, Ian, Nathan, Paul D.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2015
Materias:
Study Protocol
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4460965/
https://www.ncbi.nlm.nih.gov/pubmed/26059332
http://dx.doi.org/10.1186/s12885-015-1470-z

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4460965/
https://www.ncbi.nlm.nih.gov/pubmed/26059332
http://dx.doi.org/10.1186/s12885-015-1470-z

Ejemplares similares